Leading the Way in Life Science Technologies

GEN Exclusives

More »

Apr. 1, Vol. 25, No. 7

    • Point of View

      • Reducing Risk with
      • As the pharmaceutical industry continues to experience regulatory troubles, lackluster returns, and other setbacks, some disappointed investors may be shifting their focus from pharmaceutical companies to biotechnology companies. Investor confidenc ... more »
    • Feature Articles

      • Biotechs Focus on Critical Medical Needs
      • Biotechnology and biopharmaceutical companies were among the 230 small-cap growth companies that offered insights into their up-and-coming technologies at a conference sponsored by Roth Capital Partners (www.rothcp.com). Roth, an investment bank in ... more »
      • Michigan Life Sciences Industry Extends Roots
      • Even before the automobile industry made Michigan famous, chemical and drug pioneers set up shop in the state. In 1898, Herbert Dow began making bleach in Midland, and by 1916, Dow also produced acetylsalicyclic acid, the active ingredient in aspiri ... more »
      • Pharma Struggles with Negative Image
      • Gail Dutton
      • The pharmaceutical industry has become an easy target for critics, and that negativity is spilling over into public polls, garnering a bad reputation for the entire industry. In a Kaiser Family Foundation poll, released February 25, 70% of the 1,20 ... more »
      • Singapore Grooms Firms for Success
      • Robert Yuan, Ph.D.
      • As executives, investors, and scientists make the long trek to Asia, the central question is, why? "The drug markets in the West are mature and slow growing. The growth is in Asia and we need to be close to these emerging markets," respond ... more »
      • Trends in Viral Validation
      • Gail Dutton
      • Amidst a shortage of new, robust viral clearance and validation technology, scientists are debating the relative advantages of viral inactivation versus viral clearance, and are considering new approaches to filter retention and new orthogonal clear ... more »
      • U.S. HUPO Symposium Focuses on Proteomics
      • In the quest to unravel the mysterious behavior of proteins, scientists gathered to exchange information at the first annual "U.S. Human Proteome Organization (HUPO) Symposium," held March 13-16 in Washington, D.C. The topics ranged from p ... more »
    • Legal Affairs

      • Can a Strong Patent Position Be Illegal?
      • Antitrust laws prohibit so-called tying arrangements whereby a first product, service, or technology is bundled and sold together with a second, generally one which is less desirable or which is also available from competitors. According to the U.S ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »